CSL New Zealand Hepatitis B Immunoglobulin-VF (Human Hepatitis B Immunoglobulin), 400IU, solution for injection, vial

Land: Australien

Sprog: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv bestanddel:

hepatitis B immunoglobulin, Quantity: 160 mg/mL

Tilgængelig fra:

CSL Behring Australia Pty Ltd

INN (International Name):

hepatitis B immunoglobulin

Lægemiddelform:

Injection, solution

Sammensætning:

Excipient Ingredients: glycine

Indgivelsesvej:

Intramuscular

Enheder i pakken:

400 IU

Recept type:

(S1) This Schedule is intentionally blank

Terapeutiske indikationer:

Hepatitis B Immunoglobulin-VF is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis B antibody level is inadequate (< 10 IU/L). Post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to HBsAg-positive or suspected HBsAg-positive material, for example, by needle stick, oral ingestion or sexual exposure. Hepatitis B Immunoglobulin-VF is also indicated for prophylaxis in infants born to HBsAg-positive mothers.

Produkt oversigt:

Visual Identification: Colourless, clear to opalescent solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Autorisation status:

Listed (Export Only)

Autorisation dato:

2006-03-01